Cargando…

From Biology to Therapy: The CLL Success Story

Chemoimmunotherapy has been the standard of care for patients with chronic lymphocytic leukemia (CLL) over the last decade. Advances in monoclonal antibody technology have resulted in the development of newer generations of anti-CD20 antibodies with improved therapeutic effectiveness. In parallel, o...

Descripción completa

Detalles Bibliográficos
Autores principales:	Yosifov, Deyan Y., Wolf, Christine, Stilgenbauer, Stephan, Mertens, Daniel
Formato:	Online Artículo Texto
Lenguaje:	English
Publicado:	Wolters Kluwer Health 2019
Materias:	Review Article
Acceso en línea:	https://www.ncbi.nlm.nih.gov/pmc/articles/PMC6746030/ https://www.ncbi.nlm.nih.gov/pubmed/31723816 http://dx.doi.org/10.1097/HS9.0000000000000175

Ejemplares similares

DNA methylation of chronic lymphocytic leukemia with differential response to chemotherapy
por: Yosifov, Deyan Yordanov, et al.
Publicado: (2020)

To β or Not to β: How Important Is β-Catenin Dependent and Independent WNT Signaling in CLL?
por: Urbanek, Karol D., et al.
Publicado: (2022)

Targeted therapy in CLL: changing the treatment paradigm
por: Schneider, Christof, et al.
Publicado: (2019)

Current Treatment Options in CLL
por: Bewarder, Moritz, et al.
Publicado: (2021)

P622: GENETIC MARKERS AND OUTCOME OF CLL PATIENTS IN COMBINED TIME-LIMITED TREATMENT WITH ANTI-CD20 ANTIBODY + IBRUTINIB, IDELALISIB OR VENETOCLAX IN THE GCLLSG CLL2-BAG, -BCG, -BIG AND -BIO PHASE-II TRIALS
por: Yosifov, Deyan, et al.
Publicado: (2023)

Clonal evolution in chronic lymphocytic leukemia is scant in relapsed but accelerated in refractory cases after chemo(immune) therapy
por: Zapatka, Marc, et al.
Publicado: (2021)

Acquired BTK mutations associated with resistance to noncovalent BTK inhibitors
por: Qi, Jialei, et al.
Publicado: (2023)

P614: NOVEL SPLICE-SITE MUTATION IN PLCG2 ASSOCIATED WITH RESISTANCE TO BTK INHIBITORS
por: Qi, Jialei, et al.
Publicado: (2023)

Mutations driving CLL and their evolution in progression and relapse
por: Landau, Dan A., et al.
Publicado: (2015)

Critical molecular pathways in CLL therapy
por: Ferrer, Gerardo, et al.
Publicado: (2018)

Advances in treating chronic lymphocytic leukemia
por: Tausch, Eugen, et al.
Publicado: (2014)

Emerging Therapies in CLL in the Era of Precision Medicine
por: Iyer, Prajish, et al.
Publicado: (2023)

Polyolefins, a Success Story
por: Sauter, Dominique W., et al.
Publicado: (2017)

Sequential treatment with bendamustine, obinutuzumab (GA101) and Ibrutinib in chronic lymphocytic leukemia (CLL): final results of the CLL2-BIG trial
por: von Tresckow, Julia, et al.
Publicado: (2022)

Targeting CLL-1 for acute myeloid leukemia therapy
por: Ma, Hongbing, et al.
Publicado: (2019)

Cytotoxicity of gypsogenic acid isolated from Gypsophila trichotoma
por: Krasteva, Ilina, et al.
Publicado: (2014)

Prognostic and predictive role of gene mutations in chronic lymphocytic leukemia: results from the pivotal phase III study COMPLEMENT1
por: Tausch, Eugen, et al.
Publicado: (2020)

Editorial: Biology and treatment of high-risk CLL
por: Tausch, Eugen, et al.
Publicado: (2023)

Methylome-based cell-of-origin modeling (Methyl-COOM) identifies aberrant expression of immune regulatory molecules in CLL
por: Wierzbinska, Justyna A., et al.
Publicado: (2020)

Combination Therapy for HIV-Associated Cryptococcal Meningitis—A Success Story
por: Hurt, William J., et al.
Publicado: (2021)

Successful Anti-CLL1 CAR T-Cell Therapy in Secondary Acute Myeloid Leukemia
por: Zhang, Hui, et al.
Publicado: (2020)

Past and Present of Total Artificial Heart Therapy: A Success Story
por: Samak, Mostafa, et al.
Publicado: (2015)

Ibrutinib combinations in CLL therapy: scientific rationale and clinical results
por: Timofeeva, Natalia, et al.
Publicado: (2021)

Chimeric antigen receptor T‑cell therapy—a hematological success story
por: Wohlfarth, Philipp, et al.
Publicado: (2018)

Salary Success Story
Publicado: (1964)

Obinutuzumab plus bendamustine in previously untreated patients with CLL: a subgroup analysis of the GREEN study
por: Stilgenbauer, Stephan, et al.
Publicado: (2018)

P630: SAFETY AND TREATMENT ADHERENCE WITH ACALABRUTINIB IN VERY OLD (≥80Y) AND/OR FRAIL PATIENTS WITH CHRONIC LYMPHOCYTIC LEUKEMIA (CLL) - INTERIM SAFETY ANALYSIS OF THE ONGOING PHASE-II CLL-FRAIL TRIAL
por: Simon, Florian, et al.
Publicado: (2023)

The 10,000-Year Success Story of Wheat!
por: de Sousa, Telma, et al.
Publicado: (2021)

Selecting the optimal BTK inhibitor therapy in CLL: rationale and practical considerations
por: Lovell, Alexandra R., et al.
Publicado: (2022)

The Success Story Continues …
por: Scheffler, Ulf, et al.
Publicado: (2017)

Blockchain Success Stories
por: Hargrave, John
Publicado: (2020)

Stories for Management Success
por: Collins, David
Publicado: (2018)

Ibrutinib dose modifications in the management of CLL
por: Hardy-Abeloos, Camille, et al.
Publicado: (2020)

Results of VOICE: a global survey of disease-specific knowledge and perspectives of real-world patients with CLL
por: Tam, Constantine, et al.
Publicado: (2023)

Progressive Multifocal Leukoencephalopathy in B-CLL Successfully Treated With Venetoclax and Pembrolizumab
por: Olivieri, Jacopo, et al.
Publicado: (2022)

Biology and Treatment of High-Risk CLL: Significance of Complex Karyotype
por: Chatzikonstantinou, Thomas, et al.
Publicado: (2021)

Rotavirus Vaccines: a story of success with challenges ahead
por: O’Ryan, Miguel
Publicado: (2017)

Successful stories of drug repurposing for cancer therapy in hepatocellular carcinoma
por: Attia, Yasmeen M., et al.
Publicado: (2020)

Gene Therapy for Malignant and Benign Gynaecological Disorders: A Systematic Review of an Emerging Success Story
por: Drakopoulou, Ekati, et al.
Publicado: (2022)

Cytochromes P450: a success story
por: Werck-Reichhart, Danièle, et al.
Publicado: (2000)

Cannot write session to /tmp/vufind_sessions/sess_jopiv4e8mrobu0mm0p0qqvk5rt